Tech Transfer Roundup: Academia's Role In De-Risking Novel Science
Executive Summary
The Sanford Burnham Prebys institute is driving innovation in areas like neurodegenerative disease and immuno-oncology. Plus the latest tech transfer deals: two in cancer, one in asthma/allergies and another in lipid nanoparticle technology.
You may also be interested in...
Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Pfizer Inks Diabetes Discovery Collaboration With Sanford-Burnham
The New York-based pharma continues to delve further into the diabetes research space despite not currently having a commercial presence in the therapeutic area. Pfizer’s latest tie-up will help it identify targets that could be used in the treatment of diabetes and obesity.
Avalyn Raises $175m To Fund Inhaled Versions Of Pulmonary Fibrosis Drugs
Financing Snapshot: Seattle biotech claims its targeted, inhalable versions of Esbriet and Ofev, both oral IPF drugs, may offer better tolerability and stronger efficacy than established products.